BRPI0914121B8 - derivado de triazol ou sal do mesmo - Google Patents

derivado de triazol ou sal do mesmo

Info

Publication number
BRPI0914121B8
BRPI0914121B8 BRPI0914121A BRPI0914121A BRPI0914121B8 BR PI0914121 B8 BRPI0914121 B8 BR PI0914121B8 BR PI0914121 A BRPI0914121 A BR PI0914121A BR PI0914121 A BRPI0914121 A BR PI0914121A BR PI0914121 B8 BRPI0914121 B8 BR PI0914121B8
Authority
BR
Brazil
Prior art keywords
triazole derivative
substituted
salt
cycloalkyl
11beta
Prior art date
Application number
BRPI0914121A
Other languages
English (en)
Inventor
Sasuga Daisuke
Watanabe Hideyuki
Hoshii Hiroaki
Fukudome Hiroki
Mihara Kayoko
Shiraishi Nobuyuki
Kawano Noriyuki
Munakata Ryosuke
Yoshimura Seiji
Koike Takanori
Kawano Tomoaki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI0914121A2 publication Critical patent/BRPI0914121A2/pt
Publication of BRPI0914121B1 publication Critical patent/BRPI0914121B1/pt
Publication of BRPI0914121B8 publication Critical patent/BRPI0914121B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

derivado de triazol ou sal do mesmo é fornecido um composto que pode ser usado para prevenir ou tratar doenças, em que 11(beta)-hidroxiesteróide desidrogenase tipo 1 (11beta-hsd1) está envolvido, em particular, diabetes, resistência à insulina, demência, esquizofrenia e depressão. foi constatado que um derivado de triazol, em que uma das posições 3 e 5 do anel de triazol possui (di)alquilmetila ou cicloaquila, cada um dos quais sendo substituído com - o- (arila ou um grupo heterocíclico, cada um dos quais pode ser substituído, ou alquileno inferior-cicloalquila), e o outro deles tem arila, um grupo heterocíclico ou cicloalquila cada um dos quais pode ser substituído, ou um sal farmaceuticamente aceitável do mesmo exibe ação inibidora de 11beta-hsd1 potente. a partir do exposto acima, o derivado de triazol da presente invenção pode ser usado para prevenir ou tratar diabetes, resistência à insulina, dêmencia, esquizofrenia e depressão.
BRPI0914121A 2008-07-03 2009-07-02 derivado de triazol ou sal do mesmo BRPI0914121B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-174181 2008-07-03
JP2008174181 2008-07-03
PCT/JP2009/062081 WO2010001946A1 (ja) 2008-07-03 2009-07-02 トリアゾール誘導体またはその塩

Publications (3)

Publication Number Publication Date
BRPI0914121A2 BRPI0914121A2 (pt) 2015-10-20
BRPI0914121B1 BRPI0914121B1 (pt) 2019-08-06
BRPI0914121B8 true BRPI0914121B8 (pt) 2021-05-25

Family

ID=41466037

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914121A BRPI0914121B8 (pt) 2008-07-03 2009-07-02 derivado de triazol ou sal do mesmo

Country Status (25)

Country Link
US (1) US8377923B2 (pt)
EP (1) EP2298747B1 (pt)
JP (1) JP5494482B2 (pt)
KR (1) KR101589775B1 (pt)
CN (1) CN102076671B (pt)
AU (1) AU2009266756B2 (pt)
BR (1) BRPI0914121B8 (pt)
CA (1) CA2729408C (pt)
CY (1) CY1118501T1 (pt)
DK (1) DK2298747T3 (pt)
ES (1) ES2620657T3 (pt)
HR (1) HRP20170029T1 (pt)
HU (1) HUE031419T2 (pt)
IL (1) IL210316A (pt)
LT (1) LT2298747T (pt)
MX (1) MX2011000179A (pt)
PL (1) PL2298747T3 (pt)
PT (1) PT2298747T (pt)
RS (1) RS55664B1 (pt)
RU (1) RU2501791C2 (pt)
SI (1) SI2298747T1 (pt)
SM (1) SMT201700154T1 (pt)
TW (1) TWI465439B (pt)
WO (1) WO2010001946A1 (pt)
ZA (1) ZA201100032B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009049662A1 (de) * 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
PH12014500251A1 (en) 2011-07-29 2014-03-17 Daiichi Sankyo Co Ltd N-hetero-ring-substituted amide derivative
PL2797416T3 (pl) * 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek
KR102129150B1 (ko) * 2012-08-07 2020-07-02 바실리어 파마슈티카 아게 이사부코나졸 또는 라부코나졸의 제조 방법
CN105037285A (zh) * 2015-07-13 2015-11-11 佛山市赛维斯医药科技有限公司 三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途
MY202326A (en) * 2017-09-14 2024-04-24 Daiichi Sankyo Co Ltd Compound having cyclic structure
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
IL316907A (en) 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS
AU2024206778A1 (en) * 2023-01-06 2025-07-24 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating hsd-1-mediated disorders
CN116621735B (zh) * 2023-05-19 2025-12-19 中国医学科学院放射医学研究所 偕胺肟基团配体、及其在制备金属-有机框架材料中的应用
WO2024109642A1 (zh) * 2023-07-28 2024-05-30 常州大学 一种苯并氮杂环类化合物作为β2-肾上腺素受体别构调节剂的应用
WO2025252661A1 (en) * 2024-06-03 2025-12-11 Immunic Ag Reducing body weight and/or induction of satiety by triazolo compounds
WO2026148333A2 (en) * 2025-01-06 2026-07-09 Sparrow Pharmaceuticals, Inc. Methods and compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
DE4425144A1 (de) * 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) * 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
ATE455547T1 (de) 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
ATE476425T1 (de) 2003-05-29 2010-08-15 Merck Sharp & Dohme Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
WO2005044192A2 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
JP2005170939A (ja) * 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
US7507832B2 (en) * 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
WO2005097759A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
JP4993407B2 (ja) 2004-08-04 2012-08-08 大正製薬株式会社 トリアゾール誘導体
CN101014578B (zh) * 2004-09-16 2011-01-19 安斯泰来制药有限公司 三唑衍生物或其盐
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
JPWO2006080533A1 (ja) 2005-01-31 2008-06-19 持田製薬株式会社 ３−アミノ−１，２，４−トリアゾール誘導体
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
US8541592B2 (en) * 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
MX2008011723A (es) 2006-03-16 2008-09-26 Astellas Pharma Inc Derivado de triazol o su sal.

Also Published As

Publication number Publication date
WO2010001946A1 (ja) 2010-01-07
EP2298747B1 (en) 2016-12-28
RS55664B1 (sr) 2017-06-30
RU2011103789A (ru) 2012-08-10
MX2011000179A (es) 2011-04-05
DK2298747T3 (en) 2017-02-13
SMT201700154T1 (it) 2017-05-08
ZA201100032B (en) 2012-03-28
KR20110025688A (ko) 2011-03-10
CN102076671A (zh) 2011-05-25
BRPI0914121A2 (pt) 2015-10-20
TWI465439B (zh) 2014-12-21
JPWO2010001946A1 (ja) 2011-12-22
LT2298747T (lt) 2017-02-10
US8377923B2 (en) 2013-02-19
EP2298747A1 (en) 2011-03-23
JP5494482B2 (ja) 2014-05-14
EP2298747A4 (en) 2012-06-13
HUE031419T2 (en) 2017-07-28
IL210316A (en) 2014-07-31
HRP20170029T1 (hr) 2017-03-24
US20110105460A1 (en) 2011-05-05
TW201006804A (en) 2010-02-16
PT2298747T (pt) 2017-02-06
AU2009266756B2 (en) 2013-07-04
CA2729408A1 (en) 2010-01-07
PL2298747T3 (pl) 2017-05-31
ES2620657T3 (es) 2017-06-29
CY1118501T1 (el) 2017-07-12
RU2501791C2 (ru) 2013-12-20
KR101589775B1 (ko) 2016-01-28
BRPI0914121B1 (pt) 2019-08-06
CN102076671B (zh) 2013-05-15
IL210316A0 (en) 2011-03-31
CA2729408C (en) 2016-05-10
AU2009266756A1 (en) 2010-01-07
SI2298747T1 (sl) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1118501T1 (el) Παραγωγο τριαζολης ή αλας εξ' αυτου
WO2015017813A3 (en) Inhibitors of the farnesoid x receptor and uses in medicine
CL2007001030A1 (es) Compuestos derivados de heterociclilguanidina; y composicion farmaceutica, util para el tratamiento de la enfermedad de alzheimer, demencia senil y demencia asociada a enfermedad de parkinson entre otras.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
CL2008002542A1 (es) Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
MX2022005679A (es) Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden.
WO2010067078A3 (en) 3,6-disubstituted xanthylium salts as medicaments
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
NO20091183L (no) Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom
HK1220325A1 (zh) 苯并咪唑衍生物及其用途
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
CL2011000739A1 (es) Un compuesto 3,5-bis(3,4-dihidroxifenil)-1,2,4-triazol; composición farmacéutica que lo comprende, útil para el tratamiento de enfermedades causadas por un beta-amiloide o una sinucleinopatia, tal como enfermedad de alzheimer y enfermedad de parkinson.
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
WO2009050352A3 (fr) Derives d'imidazolones, procede de preparation et applications biologiques
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2017001926A3 (en) Therapeutic inhibitory compounds
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2017001936A3 (en) Therapeutic inhibitory compounds
CL2007002427A1 (es) Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF